BOSTON, Aug. 29, 2002 (PRIMEZONE) -- Investing in Biotechnology stocks can yield solid returns if you understand the industry, and the potential of the various companies and products they offer. Gather insights as Gerald F. Vovis, Ph.D. Executive Vice President and Chief Technology Officer at Genaissance Pharmaceuticals presents at the Boston Biotech Stocks Forum September 14 at the Seaport Hotel/World Trade Center - Boston. Delivering the keynote address will be Lynn Sutherland, President of Sutherland Consulting Inc.
The Forum will give Investors the opportunity to hear directly from company executives and get their investment information straight from the source. Investors can attend this Forum either in person at the Seaport Hotel/World Trade Center - Boston or online via www.informedinvestors.com from 9:00 a.m.-11:00 a.m. EST.
The Informed Investors Forum will include senior executives from Genaissance Pharmaceuticals (Nasdaq:GNSC), and several other firms speaking for approximately 30 minutes each with PowerPoint presentations. The keynote presentation by Lynn Sutherland will add perspective and depth to the Forum. Investors are invited to submit questions directly or by email to the executives. The forum will also be archived on www.informedinvestors.com, www.vcall.com and www.investorconference.com.
Genaissance Pharmaceuticals, Inc. is a world leader in discovering and using human gene variation to define a patient population that responds best to a medication or has a superior safety profile. The Company markets its technology and clinical development skills to the pharmaceutical and biotechnology industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance is currently applying its expertise in three therapeutic areas (central nervous system, cardiovascular and inflammation) and has agreements with three of the top five pharmaceutical companies as well as one of the premier biopharmaceutical companies: AstraZeneca, Biogen, Johnson & Johnson and Pfizer. Genaissance is located in Science Park in New Haven, Connecticut. Please visit www.genaissance.com for additional information.
Lynn Sutherland, M.S., MBA President, Sutherland Consulting, Inc., has over 20 years of technical marketing and business experience in the Life Sciences industry, including business planning and development, strategic marketing and product management. Most recently, she served as VP of Marketing at Variagenics, Inc. Variagenic's recent IPO was among the top IPOs in the emerging pharmacogenomic industry.
Prior to Variagenics, she held senior marketing and business positions in W.R. Grace (Amicon/Millipore) and Unisyn Technologies. She was also a key member of the management team in the early business development of PAREXEL, Amoco's Gene-Trak and NOVA Biomedical.
Sutherland Consulting, Inc. was founded in 2000 and focuses on Biotech start-ups. The Company works with senior management on strategic business planning, operations, marketing, PR/IR and funding. The Company works on a consortium basis bringing in specific expertise as needed. The clientele includes pharmaceutical, diagnostic, genomic/proteomic and BIO/IT companies, mainly in the near IPO stage.
Ms. Sutherland was full-time faculty at Northeastern University for six years in the disciplines of Clinical Chemistry and Immunohematology. Ms. Sutherland is an ASCP registered Medical Technologist and holds a B.S. in Medical Technology, an M.S. in Medical Laboratory Science and an MBA, all from Northeastern University.
Informed Investors is the leading producer of online and offline industry-specific investment conferences for individual investors and a member of the WILink suite of PrecisionIR(tm) services serving publicly traded companies and self-reliant investors.
About WILink
Since 1992, WILink plc (www.wilink.com) has helped public companies and mutual funds attract and retain investors. WILink's PrecisionIR(tm) and PrecisionFM(tm) custom investor-marketing programs enable publicly traded companies and mutual funds to deliver tailored and compelling communications to a precisely targeted audience of investors. This year WILink will make more than 7 million investor introductions for over 4,200 corporate clients through PrecisionIR(tm) and PrecisionFM(tm) programs, which include the Annual Reports Service, the Fund Info Service, Informed Investors Forums (www.informedinvestors.com) and Vcall(r) webcasting (www.vcall.com). WILink's InstitutionalReach(tm) database and partnerships with over 230 leading financial channels in 14 countries including The Wall Street Journal, Financial Times, Barron's and Yahoo! Finance ensure clients targeted visibility within the investment community. WILink, Inc. a wholly owned subsidiary of WILink plc (WLK: LSE) began operations in Richmond, Va. in 1993.